Frequently asked
questions

You can order PrismRA whenever you are considering RA therapy or treatment modifications for your patients. PrismRA identifies patients who are unlikely to respond to TNF inhibitor (TNFi) therapies. It can be used before you prescribe, escalate a dose, or modify treatment. The PrismRA molecular signature test was studied in biologic-naïve and biologic-exposed patients (N=730 patient samples) who had moderate-to-severe RA.1-3

PrismRA was prospectively studied in 175 biologic-naïve patients with RA enrolled in the CorEvitas Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study.1 The CERTAIN study is the largest validation and clinical utility study of its kind. Response was defined as ACR50 at 6 months post TNFi initiation. Actual patient outcomes at 6 months were cross-referenced with PrismRA results. PrismRA® identified patients who are unlikely to respond to TNFi therapies with 90% accuracy.1

Like fingerprints, molecular signatures are unique. They reveal how diseases affect each patient differently. A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior.1,4,5  These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.

PrismRA can impact prescribing decisions by identifying patients who are unlikely to respond to an TNFi therapies. Directing a patient to the correct therapy can limit the wasted time and costs of TNFi cycling, which is associated with substantial disease progression among those who fail to respond adequately.6

PrismRA gives you actionable results sorted into easy-to-interpret categories that predict a patient’s likelihood of non-response to TNFi medications: Very high: ≥95% likelihood of non-response; High: ≥90% likelihood; No Signal: Molecular signal of non-response not detected. Reports will be delivered via fax.

When modeled, PrismRA can improve patient response rates collectively for TNF inhibitor therapies and alternative MOA therapies by up to 38% by accurately stratifying patients prior to starting or changing therapy.7

Getting started is easy. Contact Scipher Medicine at 855-724-7437 or support@prismra.com to speak to a representative.

Let us know: contact Scipher Medicine at 855-724-7437 or support@prismra.com.